Opportunistic Growth: Oracle Buys Relsys to Strengthen Its eClinical Position

This Health Industry Insights Perspective examines the recently announced acquisition of Relsys International, a leading drug safety and pharmacovigilance solution provider by Oracle Corp. To us as analysts, the acquisition makes perfect sense and reinforces several important trends driving the industry today. In addressing the continuing move toward improved operational efficiency, continued critical importance of drug safety in achieving drug approvals, and growing market share in this increasingly competitive life science IT ecosystem, Oracle's acquisition of Relsys strongly complements its existing health sciences portfolio to provide its pharmaceutical and biotechnology clients with a comprehensive IT suite to advance their clinical trial efforts. While the integration of Relsys into Oracle is expected to require significant effort, the addition of this leading pharmacovigilance solution clearly strengthens Oracle's ability to respond to market needs and provides Oracle with new upsell opportunities into Relsys' substantial client base.

• In This Perspective
  • Situation Overview
    • The Convergence of eClinical IT
  • The Critical Importance of Pharmacovigilance in Drug Development
  • Fueling Business Growth at Oracle
  • Moving Forward
  • Essential Guidance
• Learn More
  • Related Research